

Payment Policy | Ultrasonographic Measurement of Carotid Intima-Medial Thickness as an Assessment of Subclinical Artherosclerosis



EFFECTIVE DATE: 10|01|2015

POLICY LAST UPDATED: 12|05|17

OVERVIEW

Ultrasonographic measurement of carotid intima-medial (or intimal-media) thickness (CIMT) refers to the use of B mode ultrasound to determine the thickness of the 2 innermost layers of the carotid artery wall, the intima and the media. Detection and monitoring of intima-medial thickening, which is a surrogate marker for atherosclerosis, may provide an opportunity to intervene earlier in atherogenic disease and/or monitor disease progression.

MEDICAL CRITERIA

Not applicable.

PRIOR AUTHORIZATION

Not applicable.

POLICY STATEMENT

BlueCHiP for Medicare and Commercial

Ultrasonographic measurement of carotid artery intima-medial thickness (CIMT) as a technique of identifying subclinical atherosclerosis is considered not medically necessary for use in the screening, diagnosis, or management of atherosclerotic disease. The existing data are insufficient to determine the impact of this technology on net health outcome.

COVERAGE

Benefits may vary between groups and contracts. Please refer to the appropriate Evidence of Coverage, Subscriber Agreement for applicable not medically necessary benefits/coverage.

BACKGROUND

Coronary heart disease (CHD) accounts for 27% of all deaths in the U.S.(1) Established major risk factors for CHD have been identified by the National Cholesterol Education Program Expert Panel (NCEP). These risk factors include elevated serum levels of low density lipoprotein (LDL) cholesterol, total cholesterol, and reduced levels of high density lipoprotein (HDL) cholesterol. Other risk factors include a history of cigarette smoking, hypertension, family history of premature CHD, and age.

The third report of the NCEP Adult Treatment Panel (ATP III) establishes various treatment strategies to modify the risk of CHD, with emphasis on target goals of LDL cholesterol. Pathology studies have demonstrated that levels of traditional risk factors are associated with the extent and severity of atherosclerosis. ATP III recommends use of the Framingham criteria to further stratify those patients with 2 or more risk factors for more intensive lipid management.(2) However, at every level of risk factor exposure, there is substantial variation in the amount of atherosclerosis, presumably related to genetic susceptibility and the influence of other risk factors. Therefore, there has been interest in identifying a technique that can improve the ability to diagnose those at risk of developing CHD, as well as measure disease progression, particularly for those at intermediate risk.

The carotid arteries can be well-visualized by ultrasonography, and ultrasonographic measurement of the CIMT has been investigated as a technique to identify and monitor subclinical atherosclerosis. B mode ultrasound is most commonly used to measure CIMT. The intima-medial thickness (IMT) is measured and averaged over several sites in each carotid artery. Imaging of the far wall of each common carotid artery yields

more accurate and reproducible IMT measurements than imaging of the near wall. Two echogenic lines are produced, representing the lumen-intima interface and the media-adventitia interface. The distance between these 2 lines constitutes the IMT.

In addition, available studies do not define how the use of CIMT in clinical practice improves outcomes. There appears to be no scientific literature that directly and experimentally tests the hypothesis that measurement of CIMT results in improved patient outcomes and no specific guidance on how measurements of CIMT should be incorporated into risk assessment and risk management. The existing data are insufficient to determine the impact of this technology on net health outcome. Therefore, CIMT is considered investigational for use in the screening, diagnosis, or management of atherosclerotic disease.

Regulatory Status

In February 2003, SonoCalc® (SonoMetric Health, LLC, Bountiful, UT) was cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510(k) process. FDA determined that this software was substantially equivalent to existing image display products for use in the automatic measurement of the IMT of the carotid artery from images obtained from ultrasound systems. Subsequently, several other devices have been approved through the 510(k) process. Product code: LLZ.

CODING

The following codes are not medically necessary:

93895 Quantitative carotid intima media thickness and carotid atheroma evaluation, bilateral
0126T Common carotid intima-medial thickness (IMT) study for evaluation of atherosclerotic burden or coronary heart disease risk factor assessment

RELATED POLICIES

None

PUBLISHED

Provider Update January 2018
Provider Update January 2017
Provider Update August 2015

REFERENCES:

1. Minino AM, Heron MP, Murphy SL, et al. Deaths: final data for 2004. *Natl Vital Stat Rep.* Aug 2007;55(19):1- 119. PMID 17867520
2. Pasternak RC. Report of the Adult Treatment Panel III: the 2001 National Cholesterol Education Program guidelines on the detection, evaluation and treatment of elevated cholesterol in adults. *Cardiol Clin.* Aug 2003;21(3):393-398. PMID 14621453
3. Den Ruijter HM, Peters SA, Anderson TJ, et al. Common carotid intima-media thickness measurements in cardiovascular risk prediction: a meta-analysis. *JAMA.* Aug 22 2012;308(8):796-803. PMID 22910757
4. van den Oord SC, Sijbrands EJ, ten Kate GL, et al. Carotid intima-media thickness for cardiovascular risk assessment: systematic review and meta-analysis. *Atherosclerosis.* May 2013;228(1):1-11. PMID 23395523
5. Lorenz MW, Polak JF, Kavousi M, et al. Carotid intima-media thickness progression to predict cardiovascular events in the general population (the PROG-IMT collaborative project): a meta-analysis of individual participant data. *Lancet.* Jun 2 2012;379(9831):2053-2062. PMID 22541275
6. Peters SA, den Ruijter HM, Bots ML, et al. Improvements in risk stratification for the occurrence of cardiovascular disease by imaging subclinical atherosclerosis: a systematic review. *Heart.* Feb 2012;98(3):177-184. PMID 22095617
7. Plichart M, Celermajer DS, Zureik M, et al. Carotid intima-media thickness in plaque-free site, carotid plaques and coronary heart disease risk prediction in older adults. The Three-City Study. *Atherosclerosis.* Dec 2011;219(2):917-924. PMID 22005196

8. Keo HH, Baumgartner I, Hirsch AT, et al. Carotid plaque and intima-media thickness and the incidence of ischemic events in patients with atherosclerotic vascular disease. *Vasc Med*. Oct 2011;16(5):323-330. PMID 21908682
9. Nambi V, Chambless L, He M, et al. Common carotid artery intima-media thickness is as good as carotid intimamedia thickness of all carotid artery segments in improving prediction of coronary heart disease risk in the Atherosclerosis Risk in Communities (ARIC) study. *Eur Heart J*. Jan 2012;33(2):183-190. PMID 21666250
10. Xie W, Liang L, Zhao L, et al. Combination of carotid intima-media thickness and plaque for better predicting risk of ischaemic cardiovascular events. *Heart*. Aug 2011;97(16):1326-1331. PMID 21653216
11. Mookadam F, Moustafa SE, Lester SJ, et al. Subclinical atherosclerosis: evolving role of carotid intima-media thickness. *Preventive cardiology*. Fall 2010;13(4):186-197. PMID 20860643
12. Dobs AS, Nieto FJ, Szklo M, et al. Risk factors for popliteal and carotid wall thicknesses in the Atherosclerosis Risk in Communities (ARIC) Study. *Am J Epidemiol*. Nov 15 1999;150(10):1055-1067. PMID 10568620
13. Chambless LE, Heiss G, Folsom AR, et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. *Am J Epidemiol*. Sep 15 1997;146(6):483-494. PMID 9290509
14. van der Meer IM, Bots ML, Hofman A, et al. Predictive value of noninvasive measures of atherosclerosis for incident myocardial infarction: the Rotterdam Study. *Circulation*. Mar 9 2004;109(9):1089-1094. PMID 14993130
15. O'Leary DH, Polak JF, Kronmal RA, et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. *N Engl J Med*. Jan 7 1999;340(1):14-22. PMID 9878640
16. Lorenz MW, Schaefer C, Steinmetz H, et al. Is carotid intima media thickness useful for individual prediction of cardiovascular risk? Ten-year results from the Carotid Atherosclerosis Progression Study (CAPS). *Eur Heart J*. Aug 2010;31(16):2041-2048. PMID 20530503
17. Folsom AR, Kronmal RA, Detrano RC, et al. Coronary artery calcification compared with carotid intima-media thickness in the prediction of cardiovascular disease incidence: the Multi-Ethnic Study of Atherosclerosis (MESA). *Arch Intern Med*. Jun 23 2008;168(12):1333-1339. PMID 18574091
18. Paramsothy P, Knopp RH, Bertoni AG, et al. Association of combinations of lipid parameters with carotid intimamedia thickness and coronary artery calcium in the MESA (Multi-Ethnic Study of Atherosclerosis). *Journal of the American College of Cardiology*. Sep 21 2010;56(13):1034-1041. PMID 20846602
19. Blaha MJ, Rivera JJ, Budoff MJ, et al. Association between obesity, high-sensitivity C-reactive protein ≥ 2 mg/L, and subclinical atherosclerosis: implications of JUPITER from the Multi-Ethnic Study of Atherosclerosis. *Arteriosclerosis, thrombosis, and vascular biology*. Jun 2011;31(6):1430-1438. PMID 21474823
20. Camhi SM, Katzmarzyk PT, Broyles ST, et al. Subclinical atherosclerosis and metabolic risk: role of body mass index and waist circumference. *Metabolic syndrome and related disorders*. Apr 2011;9(2):119-125. PMID 21133775
21. Green D, Foiles N, Chan C, et al. An association between clotting factor VII and carotid intima-media thickness: the CARDIA study. *Stroke; a journal of cerebral circulation*. Jul 2010;41(7):1417-1422. PMID 20466994
22. Bots ML, Palmer MK, Dogan S, et al. Intensive lipid lowering may reduce progression of carotid atherosclerosis within 12 months of treatment: the METEOR study. *J Intern Med*. Jun 2009;265(6):698-707. PMID 19298496
23. Raiko JR, Magnussen CG, Kivimaki M, et al. Cardiovascular risk scores in the prediction of subclinical atherosclerosis in young adults: evidence from the cardiovascular risk in a young Finns study. *European journal of cardiovascular prevention and rehabilitation: official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology*. Oct 2010;17(5):549-555. PMID 20354441
24. Baber U, Mehran R, Sartori S, et al. Prevalence, impact, and predictive value of detecting subclinical coronary and carotid atherosclerosis in asymptomatic adults: the BioImage study. *J Am Coll Cardiol*. Mar 24 2015;65(11):1065-1074. PMID 25790876

25. Johnson HM, Turke TL, Grossklaus M, et al. Effects of an office-based carotid ultrasound screening intervention. *J Am Soc Echocardiogr*. Jul 2011;24(7):738-747. PMID 21477989
26. Goff DC, Jr., Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation*. Nov 12 2013. PMID 24222018
27. Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Journal of the American College of Cardiology*. Dec 14 2010;56(25):e50-103. PMID 21144964
28. Stein JH, Korcarz CE, Hurst RT, et al. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. *J Am Soc Echocardiogr*. Feb 2008;21(2):93-111; quiz 189-190. PMID 18261694
29. Using nontraditional risk factors in coronary heart disease risk assessment: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med*. Oct 6 2009;151(7):474-482. PMID 19805770

[CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS](#)

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

